Story

Bristol Myers Squibb to Invest $2.3 Billion in New Texas Manufacturing Facility

ENTHMSVIIDZHZH-TWJAKOHI
Aug 10, 20261 min read
Bristol Myers Squibb to Invest $2.3 Billion in New Texas Manufacturing Facility
Text size
Background

Bristol Myers Squibb (NYSE: BMY) announced plans to invest approximately $2.3 billion to build a new state-of-the-art manufacturing facility in Houston, Texas. The project will significantly expand the company's U.S. production capacity and is part of a previously disclosed $40 billion commitment to invest in the United States.

Project Details and Economic Impact

The new campus will span roughly 600,000 square feet and is designed to produce a range of advanced therapeutics, including small-molecule medicines, biologics, and antibody-drug conjugates. According to the New Jersey-based drugmaker, the facility's design will allow for future expansion and reconfiguration to adapt to evolving pipeline needs.

The investment is expected to have a substantial economic impact on the region. Bristol Myers Squibb stated the project will create nearly 500 permanent skilled jobs. During the construction and launch phase, projected to run from 2027 to 2030, the company anticipates the creation of approximately 2,000 construction and related jobs.

Sample IUX Markets – In-articleAd

Broader Industry Trend

This move by Bristol Myers Squibb aligns with a broader trend among major pharmaceutical companies to increase their manufacturing footprint within the United States. This strategic onshoring aims to strengthen supply chains and respond to government incentives and pressure to produce more medicines domestically.

Other industry leaders, including Eli Lilly, Johnson & Johnson, Roche, and Pfizer, have also recently announced multi-billion dollar investments in their U.S. manufacturing operations. These commitments reflect a sector-wide response to geopolitical and economic factors, including efforts to avoid potential tariffs and ensure a stable supply of critical medicines for the U.S. market.

Read next

More on Stocks
Back to latest news

LATEST